Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

This study found no significant association between mineralocorticoid receptor antagonist therapy and mortality in patients with SARS-CoV-2 infection.

This review discusses the complex pathophysiological and clinical aspects of COVID-19, including dermatological findings and their association with SARS-CoV-2 infection but reports no new clinical results.

This study observed that in vitro exposure to dihydrotestosterone worsened COVID-19 spike protein-induced endothelial injury, while spironolactone showed potential in reducing this effect, suggesting a rationale for further evaluation in treating COVID-19.

This study found that the antiandrogen drug enzalutamide reduced TMPRSS2 levels and significantly decreased SARS-CoV-2 entry and infection in lung cells, supporting further clinical trials for COVID-19 treatment.

This study suggests that women with polycystic ovary syndrome may have an increased risk of COVID-19-related cardiac and renal complications, and that weight loss through lifestyle changes could help reduce these risks.

This review discusses possible mechanisms of SARS-CoV-2 transmission through the skin and sweat and reports no new clinical results, calling for further research on this potential route of infection.

This review explores the potential impact of SARS-CoV-2 on benign prostatic hyperplasia and related lower urinary tract symptoms but reports no new clinical results, emphasizing the need for further studies to quantify these changes.

This review discusses the potential impact of COVID-19 on the male reproductive system and highlights unanswered questions regarding its mechanisms and implications for men's health and fertility, reporting no new clinical results.

This review suggests that understanding the biological and molecular reasons for more severe COVID-19 in men, particularly those at risk for prostate cancer, could improve management of these patients, but reports no new results.

This study demonstrated that the antiandrogen drug enzalutamide may reduce TMPRSS2 levels in human lung cells and mouse lungs, supporting its potential as a COVID-19 treatment option.

This review synthesizes existing evidence on the link between androgenic alopecia and severe COVID-19 outcomes, noting a potential role for anti-androgenic therapies in treating SARS-CoV-2 infections.

This correspondence explores potential links between SARS-CoV-2 and androgenic alopecia, reporting no new clinical findings and suggesting a need for further investigative studies.

This article discusses the potential mechanism by which 5α-reductase inhibitors might offer protection against SARS-CoV-2, emphasizing possible roles of dehydroepiandrosterone and its impact on nitric oxide bioavailability, but reports no new experimental results.

This study found that lower testosterone levels in male COVID-19 patients were associated with greater disease severity and longer hospital stays.

This study explores how SARS-CoV-2 interacts with endocrine organs and highlights specific endocrine molecules that help explain the progression and outcomes of COVID-19, especially in patients with certain metabolic conditions.

This analysis discusses the role of genetic factors, particularly male hormones and specific gene variants, in influencing sex differences and potential susceptibility to severe COVID-19 outcomes, but notes that conclusive evidence is lacking, highlighting the need for larger studies.

Low testosterone levels may lead to more severe COVID-19 outcomes.

This study suggests that extracellular vesicles from prostate cancer cells could aid in identifying tumor heterogeneity and serve as biomarkers, while also playing a role in SARS-CoV-2 infection in nasopharyngeal mucus.

This study found that the antiandrogens enzalutamide and bicalutamide reduced SARS-CoV-2 entry and infection in human lung cells by lowering TMPRSS2 levels, suggesting their potential as COVID-19 treatments and supporting clinical trials.

This article discusses the potential link between genetic variants associated with androgen receptor activity and racial variations in COVID-19 mortality, suggesting a possible role for anti-androgens in treatment, but reports no new clinical findings.

This review discusses the transmission and immune response of SARS-CoV-2 and highlights ongoing research for developing vaccines and antiviral treatments, but it presents no new clinical findings.

This review summarizes current knowledge of SARS-CoV-2, including its biology, epidemiology, risk factors, and the need for updated vaccines and drugs, but presents no new clinical findings.

This review discusses the roles of sex hormones in COVID-19 progression and highlights conflicting evidence on their protective effects and the complexity of sex and gender influences on the disease.

This article reviews the structure, genomic organization, and pathogenesis of SARS-CoV-2 and discusses current efforts in prevention and treatments for COVID-19 without reporting new clinical results.

This article discusses the potential role of oral DHEA, available as a 'dietary supplement' in the US, in COVID-19 morbidity and mortality, calling for clinical trials to assess its safety.

This review discusses the dual role of testosterone in COVID-19 progression and suggests its importance in understanding the disease's mechanisms, highlighting the need for further targeted research.

This review discusses the impact of COVID-19 on the endocrine system and reports no clinical results; the authors emphasize the need to investigate endocrine damage during and after COVID-19 infection.

Men have worse COVID-19 outcomes than women due to genetic and hormonal differences.

This study reviews the mechanisms by which SARS-CoV-2 may impact male fertility, noting potential disruptions in spermatogenesis and hormone secretion, and underscores the need for follow-up in recovered men.